The Company is expanding its platform into autoimmune with two first in class new bispecific candidates entering the Company’s pipeline. The key differentiator of the ImmTAAI platform is tissue-specific down modulation of the immune system. When tethered to the tissue of interest, the new candidates supress pathogenic T cells via PD1 receptor agonism. The first candidate, IMC-S118AI, is targeted specifically to the pancreatic beta-cell and is intended for disease-modifying treatment in type 1 diabetes. IMC-S118AI recognizes a peptide from pre-proinsulin presented by HLA-A*02:01 on beta-cells. The second target is present in the skin and intended to treat inflammatory dermatological diseases. The candidate is an antigen presenting cell tethered ImmTAAI and is not HLA restricted.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on IMCR:
- Immunocore announces strategic priorities and pipeline expansion ahead of 42nd Annual J.P. Morgan Healthcare Conference presentation
- Immunocore to present at the 42nd Annual J.P. Morgan Healthcare Conference
- 3 Best Stocks to Buy Now, 11/21/2023, According to Top Analysts
- Immunocore reinstated with an Overweight at JPMorgan
- Immunocore price target lowered to $72 from $74 at Mizuho
